But today, the leading malaria vaccine candidate is in Phase III trials in seven countries across Africa.
Naye kati, abo abali mu maaso mu kaweefube w'okukola eddagala ly'omusujja bali ku mutendera ogw'okunoonyereza gwa kusatu mu nsi musanvu eza Afirika.